Otolaryngology · 2013 · 16 citations · 34 references
MedicineOncologyPathologyMolecular OncologyNeoplasiaOncogenesThyroid CancerThyroid CytologyThyroid DisordersThyroid EndocrinologyBraf V600 MutationsBraf V600e MutationClinicopathological CorrelationFollicular Thyroid NeoplasmsPapillary Thyroid Carcinoma PathologyThyroid Cancer PathologyThyroid Tumor HistopathologyWestern Blot Analysis
OBJECTIVE: We aimed to investigate the role of caveolin-1 in papillary thyroid carcinoma pathogenesis. STUDY DESIGN: Case series with chart review. SETTING: Institute for the Application of Nuclear Energy. SUBJECTS AND METHODS: We evaluated the expression of caveolin-1 in papillary thyroid carcinoma (PTC) by Western blot (WB) and compared the findings with immunohistochemical (IHC) expression of both epithelial and stromal caveolin-1 on the corresponding histological specimens. The results were related to clinicopathological features and BRAF mutation status. RESULTS: Caveolin-1 expression was found in malignant thyroid epithelium and more abundantly in tumor stroma but varied in both compartments within and between PTC subtypes. Caveolin-1 expression in the epithelium was more intense in classical PTC than in the other histological types. On the contrary, stromal caveolin-1 expression was stronger in the follicular, solid, and trabecular PTC variants than in classical PTC. Trends for down-regulation of caveolin-1 expression in epithelium and up-regulation in stroma from the classical via follicular to the solid variant were observed. The relation of WB and IHC results with clinicopathological parameters showed lower caveolin-1 tissue content in BRAF mutated tumors (P < .05), a positive correlation of epithelial caveolin-1 expression with lymph node metastasis (P < .05), and a negative association of stromal caveolin-1 expression with the degree of neoplastic infiltration and BRAF status. CONCLUSION: Altered expression of caveolin-1 in the thyroid epithelial and stromal compartments may be involved in the pathogenesis of PTC. The potential clinical significance of caveolin-1 expression, as well as its relation to BRAF mutation status, deserves further investigation.
34
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
James R. Egner · JAMA · 2010 · 6.1K citations
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text
BRAF Mutation in Papillary Thyroid Carcinoma
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo et al. · JNCI Journal of the National Cancer Institute · 2003 · 924 citations · Full text